Background: In western Mexico, the Magnolia pacifica complex includes three morphologically defined, endemic and, endangered species, distributed along a 215 km continentality and moisture gradient: Magnolia pugana, M. pacifica s.s., and M. vallartensis. Hypothesis: Genetic evidence supports the taxonomical classification of the M. pacifica complex. Study site and dates: Western Mexico, samples were collected in 2012-2015. Methods: Six Inter-Simple Sequence Repeats (ISSR) primers amplified 76 clear and reproducible fragments in 278 individuals from 10 localities representative of the M. pacifica complex. ISSR dataset was analyzed using STRUCTURE 2.3.4, UPGMA clustering, Barrier 2.2, and AMOVA. Genetic diversity parameters were also estimated. Results: Genetic analyses revealed two main groups: M. pugana and M. pacifica s.s.–M. vallartensis. Two subpopulations within each group were evidenced, particularly M. pacifica s.s. was separated from M. vallartensis. Geographical barriers to gene flow were identified. AMOVA revealed a similar and significant proportion of variation between and within groups. M. pugana has lower genetic diversity and higher differentiation than the M. pacifica s.s-M. vallartensis group. Conclusions: Our results support the recognition of M. pugana as a genetically distinct lineage from M. pacifica s.s and M. vallartensis, but did not reveal a clear species boundary between the last two taxa. Geographical barriers and distance isolation might explain the genetic structure and differentiation pattern within the M. pacifica s.s. species complex. All main groups and subgroups defined in this study should be considered as separate conservation units, and concerted efforts are needed to protect them.

Background: Several studies have shown that patients with cancer have antibodies in serum that react with cellular autoantigens, known as Tumor-Associated Antigens (TAA). The present work aimed to determine whether a mini-array comprising four recombinant TAA increases the detection of specific serum antibodies for the diagnosis of early-stage breast cancer. Methods: The mini-array included Alpha 1-AntiTrypsin (A1AT), TriosePhosphate Isomerase 1 (TPI1), Peptidyl-Prolyl cis-trans Isomerase A (PPIA), and PeroxiReDoXin 2 (PRDX2) full-length recombinant proteins. The proteins were produced after gene cloning, expression, and purification, and were verified by Western blot assays. Then, Dot-Blot was performed to find antibodies against the four TAA in 12 sera from women with early-stage breast cancer (stage II) and 12 sera from healthy women. Results: Antibody detection against individual TAA in early-stage breast cancer sera ranged from 58.3% to 83.3%. However, evaluation of the four TAA showed that there was a positive antibody reaction reaching a sensitivity of 100% and a specificity of 85% in early-stage breast cancer, suggesting that this mini-array must be evaluated as a clinical diagnostic tool for early-stage breast cancer in a larger sample size. Conclusion: Our results suggest that TAA mini-arrays may provide a promising and powerful method for improving the detection of breast cancer in Mexican women.

This study aimed to summarize the epidemiological and clinical characteristics of COVID-19 from Western Mexico people during 2020. A retrospective analysis from an electronic database of people visiting a sentinel center for molecular SARS-CoV-2 confirmatory diagnosis by RT-PCR from April to December 2020 was carried out for epidemiological and clinical description of COVID-19. Out of 23,211 patients evaluated, 6918 (29.8%) were confirmed for SARS-CoV-2 infection (mean age 38.5 ± 13.99), mostly females (53.8%). Comorbidities, such as diabetes (34.7%), obesity (31.15%), and hypertension (31.8%), presented an increased odds OR = 1.27, CI = 1.14–1.41; OR = 1.08, CI = 1.01–1.16; and OR = 1.09, CI = 0.99–1.19, respectively, for viral-infection. Moreover, fever, headache, and dry cough were the most frequent symptoms. No infection difference among sex was found. Those patients >60 years old were prone to COVID-19 severity (OR = 3.59, CI = 2.10–6.14), evaluated by the number of manifested symptoms, increasing with age. In conclusion, a high SARS-CoV-2 prevalence was found in Western Mexico. Comorbidities were frequent in infected people; nevertheless, no association with disease outcomes was observed, in contrast with the highest disease severity risk found in older patients; however, continuous monitoring should be carried since comorbidities have been reported as aggravating factors. This study can help the health officials for the elaboration of planning efforts of the disease management and others in the future.